Leonardo Roever Shares a Study on Eligibility Criteria for Endovascular Thrombectomy
Leonardo Roever, CEO of Brazilian Evidence-Based Health Network, shared on LinkedIn:
”Endovascular Thrombectomy for Acute Stroke: Evolving Eligibility Criteria and Adjuvant Therapies
In this review, the authors present recent developments, highlighting how biological targets align with the pathophysiological chronology of primary and secondary injury after an ischemic stroke.
It also discusses why some clinical trials have demonstrated success and others may not, and proposes important considerations for the planning of future trials.
This synthesis aims to inform about the evolving evidence for the treatment of acute ischemic stroke and inspire the planning of clinical trials and next-generation therapies.
See the article.
Follow me for more content on evidence, management, and innovation in healthcare!”
Read the full article here.
Article: Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies
Authors: Martina Glavan, Jia Liu, Gisele Sampaio Silva, Thanh N Nguyen, Jiangbing Zhou, Nenad Sestan et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 07:14Oliver Tiebel: Antiphospholipid Syndrome in Pregnancy – One of Hematology’s Most Complex Challenges
-
Apr 6, 2026, 06:25Katherine Bridge: My First Time at The EHA ReCon
-
Apr 6, 2026, 06:11Priya Prasad: Family Donations Are Not as Safe as We Usually Think
-
Apr 6, 2026, 05:48Isaac Okello: Turning Point from Reliance on Foreign Exports to Self – Reliance Through Local Production of Medical Supplies
-
Apr 6, 2026, 05:34Lena Volland: Scientific Exchange in Bleeding Disorders at the WFH 2026 World Congress
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients